These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16601783)

  • 21. Suckling rat brain regional distribution of acetylcholinesterase activity in galactosaemia in vitro.
    Marinou K; Tsakiris S; Tsopanakis C; Schulpis KH; Behrakis P
    Metab Brain Dis; 2005 Sep; 20(3):227-36. PubMed ID: 16167200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
    Nordberg A; Darreh-Shori T; Peskind E; Soininen H; Mousavi M; Eagle G; Lane R
    Curr Alzheimer Res; 2009 Feb; 6(1):4-14. PubMed ID: 19199870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nicotinic component of galantamine in the regulation of amyloid precursor protein processing.
    Lenzken SC; Lanni C; Govoni S; Lucchelli A; Schettini G; Racchi M
    Chem Biol Interact; 2007 Jan; 165(2):138-45. PubMed ID: 17196952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An update on the pharmacology of galantamine.
    Villarroya M; García AG; Marco-Contelles J; López MG
    Expert Opin Investig Drugs; 2007 Dec; 16(12):1987-98. PubMed ID: 18042006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors.
    Barnes CA; Meltzer J; Houston F; Orr G; McGann K; Wenk GL
    Neuroscience; 2000; 99(1):17-23. PubMed ID: 10924948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of purinergic neurotransmission by galantamine and other acetylcholinesterase inhibitors in the rat vas deferens.
    Caricati-Neto A; D'angelo LC; Reuter H; Hyppolito Jurkiewicz N; Garcia AG; Jurkiewicz A
    Eur J Pharmacol; 2004 Oct; 503(1-3):191-201. PubMed ID: 15496314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat.
    De Sarno P; Pomponi M; Giacobini E; Tang XC; Williams E
    Neurochem Res; 1989 Oct; 14(10):971-7. PubMed ID: 2608162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of cholinesterase inhibition in vitro by huperzine analogs.
    Tang XC; Xu H; Feng J; Zhou TX; Liu JS
    Zhongguo Yao Li Xue Bao; 1994 Mar; 15(2):107-10. PubMed ID: 8010100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversible acetylcholinesterase inhibitory effect of Tabernaemontana divaricata extract on synaptic transmission in rat CA1 hippocampus.
    Pratchayasakul W; Pongchaidecha A; Chattipakorn N; Chattipakorn SC
    Indian J Med Res; 2010 Mar; 131():411-7. PubMed ID: 20418555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mixed-effect circadian rhythm model for human erythrocyte acetylcholinesterase activity--application to the proof of concept of cholinesterase inhibition by acorn extract in healthy subjects with galantamine as positive control.
    Han S; Lee J; Jeon S; Hong T; Yim DS
    Eur J Clin Pharmacol; 2012 May; 68(5):599-605. PubMed ID: 22207414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use.
    Wenk GL; Quack G; Moebius HJ; Danysz W
    Life Sci; 2000 Feb; 66(12):1079-83. PubMed ID: 10737358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antioxidative properties of galantamine on neuronal damage induced by hydrogen peroxide in SK-N-SH cells.
    Ezoulin MJ; Ombetta JE; Dutertre-Catella H; Warnet JM; Massicot F
    Neurotoxicology; 2008 Mar; 29(2):270-7. PubMed ID: 18191456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine.
    Darreh-Shori T; Kadir A; Almkvist O; Grut M; Wall A; Blomquist G; Eriksson B; Långström B; Nordberg A
    Neurobiol Aging; 2008 Feb; 29(2):168-84. PubMed ID: 17196712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. l-Hypaphorine and d-hypaphorine: Specific antiacetylcholinesterase activity in rat brain tissue.
    Yonekawa MKA; Penteado BB; Dal'Ongaro Rodrigues A; Lourenço EMG; Barbosa EG; das Neves SC; de Oliveira RJ; Marques MR; Silva DB; de Lima DP; Beatriz A; Oses JP; Dos S Jaques JA; Santos EDAD
    Bioorg Med Chem Lett; 2021 Sep; 47():128206. PubMed ID: 34146704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of a Novel Acetylcholinesterase Inhibitor by Fragment-Based Design and Virtual Screening.
    Stavrakov G; Philipova I; Lukarski A; Atanasova M; Georgiev B; Atanasova T; Konstantinov S; Doytchinova I
    Molecules; 2021 Apr; 26(7):. PubMed ID: 33916760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of the acetylcholinesterase inhibitor galanthamine.
    Sramek JJ; Frackiewicz EJ; Cutler NR
    Expert Opin Investig Drugs; 2000 Oct; 9(10):2393-402. PubMed ID: 11060814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Novel Galantamine-Curcumin Hybrid as a Potential Multi-Target Agent against Neurodegenerative Disorders.
    Simeonova R; Zheleva D; Valkova I; Stavrakov G; Philipova I; Atanasova M; Doytchinova I
    Molecules; 2021 Mar; 26(7):. PubMed ID: 33806197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of subchronic galantamine treatment on neuronal nicotinic and muscarinic receptor subtypes in transgenic mice overexpressing human acetylcholinesterase.
    Svedberg MM; Bednar I; Nordberg A
    Neuropharmacology; 2004 Sep; 47(4):558-71. PubMed ID: 15380373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of New Galantamine Derivatives in a Scopolamine Model of Dementia in Mice.
    Lazarova M; Tancheva L; Alexandrova A; Tsvetanova E; Georgieva A; Stefanova M; Tsekova D; Vezenkov L; Kalfin R; Uzunova D; Petkova-Kirova P
    J Alzheimers Dis; 2021; 84(2):671-690. PubMed ID: 34569967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.